Matches in Wikidata for { <http://www.wikidata.org/entity/Q66062581> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- Q66062581 description "clinical trial" @default.
- Q66062581 description "ensayu clínicu" @default.
- Q66062581 description "klinisch onderzoek" @default.
- Q66062581 description "клінічне випробування" @default.
- Q66062581 name "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies" @default.
- Q66062581 name "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies" @default.
- Q66062581 type Item @default.
- Q66062581 label "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies" @default.
- Q66062581 label "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies" @default.
- Q66062581 prefLabel "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies" @default.
- Q66062581 prefLabel "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies" @default.
- Q66062581 P1050 Q66062581-3CCC9793-0A48-4F7E-B490-ECEB2B53B2B9 @default.
- Q66062581 P1132 Q66062581-8663E9C2-867E-4B3F-9AEA-3C9383725F6E @default.
- Q66062581 P131 Q66062581-C848A36F-8DA5-4BC9-9C8A-02216A8FBE73 @default.
- Q66062581 P1476 Q66062581-B2F44093-5B92-443E-8236-9464EC48B1C2 @default.
- Q66062581 P17 Q66062581-06860A0E-DCB0-4762-9B47-A269D90DBFFA @default.
- Q66062581 P17 Q66062581-26737D95-1720-4A6A-998E-C6C1109DC982 @default.
- Q66062581 P17 Q66062581-54399A51-7878-42AB-85A8-7C37B7430D8A @default.
- Q66062581 P17 Q66062581-66A643AD-FE8E-407D-B027-FDAD1F0EA862 @default.
- Q66062581 P17 Q66062581-9ABD8478-087A-4B34-8F6C-CF5B5CA77CE9 @default.
- Q66062581 P17 Q66062581-A406A8BD-75AF-4DAF-9DB5-6BAFF45942FE @default.
- Q66062581 P17 Q66062581-B5741C7E-5A8B-4C56-88E3-F481AAF61EA2 @default.
- Q66062581 P17 Q66062581-C2922E1C-BE67-44CC-8453-5DE562E01D92 @default.
- Q66062581 P17 Q66062581-D3A2D17B-8CE2-4D70-8A23-28BEBF333D8D @default.
- Q66062581 P17 Q66062581-E8D70FFA-E638-42A6-B3CB-DD597BA0A4C2 @default.
- Q66062581 P2899 Q66062581-72B1F05F-933F-4D56-8985-289313986C2F @default.
- Q66062581 P3098 Q66062581-EBB1B9BD-DCD4-458F-BFF3-440ACD8B9E3D @default.
- Q66062581 P31 Q66062581-75B0F9D4-B490-486F-8234-4F2643D9AB87 @default.
- Q66062581 P580 Q66062581-2434B8BE-7064-444A-8D8A-E7616FE2053B @default.
- Q66062581 P582 Q66062581-B0054D8F-1C4F-4169-9807-D1505D619377 @default.
- Q66062581 P6099 Q66062581-7DE31656-BE57-4A56-BF4E-C8C361F201A5 @default.
- Q66062581 P6153 Q66062581-7DB4FEC2-F7E3-4402-96B0-519A51A71A9F @default.
- Q66062581 P8363 Q66062581-8EB0B76D-37F7-4E69-9C4D-1496C051329B @default.
- Q66062581 P859 Q66062581-E44DAAC8-FED3-43E9-A1C0-96199125E687 @default.
- Q66062581 P1050 Q33525 @default.
- Q66062581 P1132 "+126" @default.
- Q66062581 P131 Q8646 @default.
- Q66062581 P1476 "A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies" @default.
- Q66062581 P17 Q17 @default.
- Q66062581 P17 Q183 @default.
- Q66062581 P17 Q20 @default.
- Q66062581 P17 Q29 @default.
- Q66062581 P17 Q30 @default.
- Q66062581 P17 Q31 @default.
- Q66062581 P17 Q33 @default.
- Q66062581 P17 Q334 @default.
- Q66062581 P17 Q408 @default.
- Q66062581 P17 Q865 @default.
- Q66062581 P2899 "+18" @default.
- Q66062581 P3098 "NCT04000529" @default.
- Q66062581 P31 Q30612 @default.
- Q66062581 P580 "2019-07-05T00:00:00Z" @default.
- Q66062581 P582 "2020-07-03T00:00:00Z" @default.
- Q66062581 P6099 Q5452194 @default.
- Q66062581 P6153 Q507154 @default.
- Q66062581 P8363 Q78089383 @default.
- Q66062581 P859 Q507154 @default.